Radka Fahey

Starting Investigator

National Institute for Bioprocessing Company Profiles.
Radka Fahey.
Iain White/Fennell Photography.
Fennell Photography 2017.

Radka Fahey

Starting Investigator
View Publications

Dr Fahey joined the GlycoScience group in May 2005 as a Research Assistant and defended her PhD at the Institute of Chemical Technology Prague in November 2007. She continued as a Postdoctoral Researcher working on cancer glycobiomarkers and glycan analysis.

Dr Fahey has been awarded an SFI Starting Investigator research grant (SIRG) for “Epigenetic regulation of glycosylation and the impact on chemoresistance in cancer” which commenced in October 2014. This project follows on from novel published findings demonstrating that changes in DNA methylation in ovarian cancer cells are concomitant with significant alterations in the expression of key enzymes that form part of glycosylation. Epigenetic alterations, tumour hypoxia and glycosylation are integral aspects of carcinogenesis. Determining the mechanism of epigenetic regulation of glycosylation and the link with hypoxia and drug resistance will help to improve the treatment of cancer patients by evaluating drugs such as 5-AZA, which is already in clinical trials. Little is known about the impact of this treatment on cellular glycosylation and the ability of cancer cells to bypass apoptotic cell death mechanisms.

We expect to provide new insights into the mechanism of these events and identify patients who are resistant to cis-platinum and ultimately improve the treatment and prognosis for these patients.

This SFI Investigator Award also funds a PhD studentship, Mr Gordon Greville.

Her other interests include the development and utilisation of high-throughput technologies for glycan analysis as well as detailed glycan characterization, clinical marker discovery and role of system biology in regulation of glycosylation in cancer and inflammatory diseases.

Research Areas

-Epigenetic regulation of glycosylation and the impact on chemoresistance in cancer, glycosylation control for advanced drug manufacture, provision of glycan markers for advanced therapy and medicinal products (ATMPs)

-Development and utilisation of high throughput automated, quantitative, sensitive glycan analysis; glycan profiling and complete glycan characterization

-Applications of our technology to determine roles for glycosylation on safety and improved efficacy of current drug and future drugs and therapeutics